Safety and efficacy of tazarotene foam for the treatment of acne vulgaris

14Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. © 2013 Epstein and Gold, publisher and licensee Dove Medical Press Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Epstein, E. L., & Gold, L. S. (2013, May 13). Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clinical, Cosmetic and Investigational Dermatology. https://doi.org/10.2147/CCID.S34054

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free